Supplementary Data 2 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance

Mellone M.; Piotrowska K.; Venturi G.; James L.; Bzura A.; Lopez MA.; James S.; Wang C.; Ellis MJ.; Hanley CJ.; Buckingham JF.; Cox KL.; Hughes G.; Valge-Archer V.; King EV.; Beers SA.; Jaquet V.; Jones GDD.; Savelyeva N.; Sayan E.; Parsons JL.; Durant S.; Thomas GJ.

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Supplementary Data 2 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance

Mellone M., Piotrowska K., Venturi G., James L., Bzura A., Lopez MA., James S., Wang C., Ellis MJ., Hanley CJ., Buckingham JF., Cox KL., Hughes G., Valge-Archer V., King EV., Beers SA., Jaquet V., Jones GDD., Savelyeva N., Sayan E., Parsons JL., Durant S., Thomas GJ.

<p>list of primer sequences, antibody details and primary fibroblasts used</p>

Original publication

DOI

10.1158/0008-5472.22432578

Type

Other

Publication Date

31/03/2023